Novo Nordisks CagriSema Shows Strong Weight-Loss Results But Trails Eli Lillys Tirzepatide in Latest Clinical Data Feb 26, 2026 A New Chapter in the Global Anti-Obesity Drug Race The competition to develop next-generation obesity therapies intensified following the release of new Phase III clinical data for CagriSema, an investigational drug from Novo Nordisk
*Correspondence: Xiao-Yin Wang, [email protected] These authors share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Apparently, the use of 24 mg/kg of L-carnitine in the diets of the animals under study (85-95 weeks) did not influence on protein synthesis in albumen and, therefore, on the height of this edible structure (albumen) and Haugh unit (table 3), since these indicators (albumen height and Haugh unit) are highly correlated and are considered for evaluating egg freshness and its storage time on the shelf (Martnez et al
Neurotherapeutics (2010) 7:2419.10.1016/j.nurt.2010.05.004 20 FryeREDelatorreRTaylorHBSlatteryJMelnykSChowdhuryNet alMetabolic effects of sapropterin treatment in autism spectrum disorder: a preliminary study
Arabidopsis glutathione-S-transferases GSTF11 and GSTU20 function in aliphatic glucosinolate biosynthesis
